Schizophrenia/Psychosis

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

Knowing the difference between one condition and another is critical, even when the precise diagnosis is unclear.

The abysmal conditions in state mental hospitals in the 1940s were caused by 3 factors, none of which are now true. Let’s explore.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.

The data assess the extended efficacy of the treatment for up to 4 years.

The device is currently under clinical trial investigation as an adjunct treatment to standard of care therapy for experiential negative symptoms of schizophrenia.

New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.

The experts weighed in on a wide variety of psychiatric issues for the December 2023 issue of Psychiatric Times.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

What is new in research on schizophrenia?

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?

Researchers performed a systematic review and meta-analysis of the effects of clozapine on cognitive function in patients with treatment-resistant schizophrenia.

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.

Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

From dopamine detoxification for problem gaming to connections between bacteria and anxiety and depression, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of November.

The FDA’s decision is set for September 2024.

Examine this case in which a patient presents with extreme constipation.

Young men appear to be particularly susceptible to the effects of cannabis on schizophrenia.

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.